TNF and melanoma: In melanoma, TAM-derived TNFα mediated resistance to MAPK pathway inhibitors, and applying TNFα signaling inhibitor targeted the cancer cells and TME sensitizing the tumor to immunotherapy (Smith et al., 2014).